Steven Mottl, DO
Cardiovascular Disease · Tucson, AZNPI 1104003748
Payments from drug & device makers
Across 642 payments — averaging $528.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lantheus Medical Imaging, Inc.$328K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$5K
- Novartis$915
- Heartflow, Inc.$822
- Pfizer$708
- Merck$570
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$282,61583%
- Travel & lodging$42,94713%
- Food & beverage$13,6784%
- Education$3080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lantheus Medical Imaging, Inc. | 330 | $328,099 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $5,186 |
| Novartis | 43 | $915 |
| Heartflow, Inc. | 16 | $822 |
| Pfizer | 40 | $708 |
| Merck | 39 | $570 |
| Amgen | 25 | $447 |
| Astellas Pharma US Inc | 12 | $380 |
| Sanofi-aventis U.S. LLC | 14 | $303 |
| Esperion Therapeutics, Inc. | 21 | $288 |
| E.r. Squibb & Sons, L.L.C. | 12 | $200 |
| Johnson & Johnson | 10 | $171 |
| Novo Nordisk | 7 | $141 |
| Actelion Pharmaceuticals US, Inc. | 3 | $135 |
| Regeneron | 1 | $123 |
| AstraZeneca | 6 | $103 |
| Endologix LLC | 1 | $101 |
| Kestra Medical Technology Services, Inc. | 3 | $94 |
| Philips North America LLC | 4 | $93 |
| Abbott | 3 | $86 |
| Boehringer Ingelheim | 4 | $85 |
| Amarin Pharma, Inc. | 4 | $69 |
| Inspire Medical Systems, Inc. | 3 | $61 |
| Medtronic | 2 | $52 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| Irhythm Technologies, Inc. | 2 | $39 |
| Medicomp Inc | 1 | $32 |
| Abiomed | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Boston Scientific | 1 | $26 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Cvrx, Inc. | 1 | $15 |
| Atricure, Inc. | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
| Angiodynamics, Inc. | 1 | $12 |
| Siemens Medical Solutions USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Definity$324,073
- LifeVest$4,722
- FFRct$526
- PRALUENT$239
- ELIQUIS$118
- Torus Stent Graft System$101
- ENDOCROSS Device$101
How this compares
$339,548 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 321 | $394,432 |
| XareltoRivaroxaban | 110 | $132,141 |
| EntrestoSacubitril/Valsartan | 99 | $112,324 |
| Repatha SureclickEvolocumab | 90 | $94,954 |
| NexlizetBempedoic Acid/Ezetimibe | 46 | $33,708 |
| CorlanorIvabradine Hcl | 22 | $21,865 |
| Ranolazine ErRanolazine | 113 | $10,481 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 29 | $9,629 |
| Rosuvastatin Calcium | 660 | $7,417 |
| NexletolBempedoic Acid | 13 | $5,871 |
| Flecainide Acetate | 130 | $5,357 |
| SotalolSotalol Hcl | 164 | $3,828 |
| Clonidine | 22 | $3,710 |
| Metoprolol Succinate | 253 | $3,464 |
| Nebivolol Hcl | 91 | $3,301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $708 | $394,432321 claims |
| Johnson & JohnsonXarelto | $171 | $132,141110 claims |
| NovartisEntresto | $915 | $112,32499 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $288 | $39,58059 claims |
| AmgenCorlanor | $447 | $21,86522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Tucson
- Gregory KoshkarianTucson$608K
- Karl KernTucson$174K
- Marvin SlepianTucson$106K
- Elizabeth JunemanTucson$81K
- Stephen AlgeoTucson$53K
- Monty MoralesTucson$39K
- Christopher AngusTucson$35K
- Hoang ThaiTucson$30K
- David RizikScottsdale$2.1M
- Rodrigo ChanMesa$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.